Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01900275 · ClinicalTrials.gov registry record

Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults

A clinical trial, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
57
Enrollment target

NCT01900275: Completed study, sponsored by Denver Health and Hospital Authority.

NCT01900275 is a clinical trial that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01900275 has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
57 participants
Enrollment target

Study Summary

Across the world, the most common cause of dying in the ICU is a disease called "sepsis". Sepsis is a disease in which the body's protective response to infection becomes too intense, unnecessarily damaging important organs in the body. Kidney damage during sepsis is particularly bad, as a person's chance of survival drops significantly when he or she develops kidney failure. This study plans to learn more about how to detect (and thus prevent) kidney failure early in sepsis. The current tests doctors use only detect kidney failure once it's already happened. We must therefore find better ways of detecting kidney failure earlier, when there is still a chance to protect the kidneys. In this study, patients will provide a one-time sample of urine. We will check this urine for signs of a protein called "heparanase", which we believe is important in early kidney failure. We will then see if high heparanase activity in urine predicts the risk of developing kidney failure. We will compare results from patients with sepsis with results from patients with trauma, allowing us to determine if heparanase is only important in sepsis kidney failure.

Primary Outcome

Acute kidney injury will be determined using RIFLE criteria, based upon change in serum creatinine or urine output.

Interventions

  • OTHER Urine collection

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2013-07

What the finished NCT01900275 record still lists

NCT01900275 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Urine collection is the first listed.

NCT01900275 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01900275 about?

NCT01900275 is a clinical study titled "Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults". Across the world, the most common cause of dying in the ICU is a disease called "sepsis". Sepsis is a disease in which the body's protective response to infection becomes too intense, unnecessarily damaging important organs in the body. Kidney damage during sepsis is particularly bad, as a person's ...

What is the current status of trial NCT01900275?

This trial is currently completed. The enrollment target is 57 participants. The study started on 2013-07.

What interventions are being tested in trial NCT01900275?

The interventions under investigation include: Urine collection (OTHER).

Who is sponsoring clinical trial NCT01900275?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01900275, the US trial registry maintained by the National Library of Medicine. NCT01900275 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.